FLUARIX TETRA (GlaxoSmithKline Australia Pty Ltd)
Product name
FLUARIX TETRA
Date registered
Evaluation commenced
Decision date
Approval time
225 working days (255)
Active ingredients
influenza virus haemagglutinin
Registration type
EOI
Indication
FLUARIX TETRA (quadrivalent vaccine) is now also indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types A and B contained in the vaccine.